BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BIODESIX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.40−0.26 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
BIODESIX INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Tests | $92.62M | $85.17M | $79.20M | $71.25M | $68.59M | $67.23M | $64.71M | $60.30M | $55.43M | $50.34M | $45.19M | $40.65M | 90.0% | +35.0% |
| Development Services | $10.32M | $10.92M | $9.30M | $8.92M | $7.97M | $7.24M | $6.62M | – | – | – | – | – | 10.0% | +29.5% |
| Services and Other | – | – | – | – | – | – | – | – | – | – | – | $3.38M | – | – |
| Biopharma Services and Other | – | – | – | – | – | – | – | $5.26M | $5.47M | $4.51M | $3.90M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Biodesix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.